According to Fortune, longevity science stands on the cusp of major AI-driven breakthroughs, but significant data gaps threaten to undermine progress. At the Fortune Global Forum in Riyadh, experts including HRH Princess Dr. Haya bint Khaled bin Bandar Al Saud of Hevolution Foundation highlighted critical shortages in biological, demographic, and epidemiological data needed to understand how cells and organs age. Insilico Medicine CEO Alex Zhavoronkov revealed his company has 30 AI-based projects targeting dual-purpose drugs that address both diseases and aging simultaneously, while NABTA Health founder Sophie Smith emphasized that fewer than 1% of clinical trial participants are women of Middle Eastern, South Asian, and African origin. The panelists agreed that current healthcare frameworks fail to collect data early enough in life, with aging research typically focusing on older populations despite aging processes beginning much earlier.
Table of Contents
The Data Diversity Crisis in Aging Research
The historical exclusion of diverse populations from clinical research represents more than just an equity issue—it’s a fundamental scientific problem that could render AI models ineffective for large segments of humanity. When AI systems are trained predominantly on data from Western male populations, they develop biases that may lead to inaccurate predictions and ineffective treatments for women and non-Western ethnic groups. This problem is particularly acute in aging science because biological aging processes differ significantly between genders and across ethnicities due to genetic variations, environmental factors, and lifestyle differences. The consequences extend beyond individual health outcomes to potentially wasting billions in research funding on interventions that only work for narrow demographic slices.
The Early Screening Revolution We Need
Current healthcare models treat aging as a problem of later life, but the most promising interventions will likely need to begin decades earlier. The traditional approach of screening for age-related conditions only after symptoms appear misses the window when preventive measures could be most effective. As Hevolution Foundation’s research leadership suggests, we need to fundamentally rethink when we begin monitoring aging biomarkers—potentially starting in adolescence or early adulthood. This represents a paradigm shift from reactive medicine to proactive health optimization, requiring new regulatory frameworks, ethical guidelines, and public acceptance of lifelong health monitoring. The technological infrastructure for such comprehensive longitudinal data collection doesn’t yet exist at scale, presenting both a challenge and opportunity for healthcare innovators.
The Promise and Peril of Dual-Purpose Drug Discovery
The strategy pursued by companies like Insilico Medicine to develop drugs that target both specific diseases and aging processes represents a clever approach to regulatory and commercialization challenges. By demonstrating efficacy against established diseases first, these treatments can navigate existing FDA pathways while potentially delivering broader anti-aging benefits. However, this approach carries significant risks—the same biological mechanisms that might extend healthspan could have unforeseen side effects when manipulated systemically. The first AI-discovered drug to demonstrate credible aging reversal will face intense scrutiny from regulators concerned about long-term safety and the ethical implications of fundamentally altering human aging. Success will require not just scientific validation but also careful public communication about realistic expectations.
The Critical Gender Divide in Healthspan
The different aging patterns between men and women highlighted by experts like NABTA Health’s Sophie Smith reveal fundamental biological differences that most longevity research has overlooked. Women’s unique hormonal transitions, particularly around menopause, create distinct health challenges that require specialized interventions rather than simply applying male-derived models. The fact that women spend more of their middle years in relative ill-health despite longer overall lifespans represents both a humanitarian concern and massive economic burden. Addressing this gap will require developing female-specific biomarkers, designing clinical trials that account for hormonal cycles, and creating interventions tailored to women’s unique aging trajectories. The non-profit research sector may need to lead this charge, as pharmaceutical companies have historically underinvested in female-specific health research.
A Realistic Timeline for Longevity Breakthroughs
While the field buzzes with excitement, the 20-year horizon for “dramatic events” in aging science suggested by industry leaders represents a more measured assessment than the hyperbolic claims often seen in popular media. True breakthroughs that significantly extend human healthspan will require not just scientific discovery but also the development of robust safety profiles, scalable manufacturing, and accessible delivery systems. The transition from laboratory success to widespread clinical impact typically takes decades, even for conventional therapies—and aging interventions face additional regulatory hurdles as they represent a new category of treatment. The most likely near-term impact will come from repurposed existing drugs and lifestyle interventions informed by AI analysis of large datasets, while more radical lifespan extension technologies remain further on the horizon.
